Mitoxantrone in the Treatment of Acute Leukemia

Coccia-Portugal, Maria A.; Falkson, Geoffrey; Uys, André

doi:10.1007/978-3-642-74643-7_59

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[91] Of 49 patients who had received mitoxantrone and cytarabine in a further study, 4 showed signs of CHF, although this was attributed in all cases to intravenous fluid overload) 102] Decreases in ejection fraction (11 to 14% relative to baseline) were seen in 3 of 62 patients after mitoxantrone 12 mg/m 2 for 5 days.…”

Section: Cardiotoxicitymentioning

confidence: 99%

Mitoxantrone

Dunn¹,

Goa²

1996

Drugs & Aging

View full text Add to dashboard Cite

Acute nonlymphoblastic leukaemia (ANLL) is a malignant condition strongly associated with advancing age. Of adult acute leukaemias, 80 to 85% are classified as ANLL, with more than half of all patients being aged over 60 years. Although advancing age has been reported to be a poor prognostic factor in ANLL, recent clinical trials have shown good results in patients aged 60 years and over after coadministration of the anthracenedione antineoplastic agent mitoxantrone with cytarabine. In 1 study in particular, which involved patients aged 60 to 81 years, no correlation was found between increasing age and response rate. However results of a major clinical trial showed age greater than 60 years to be associated with poorer outcomes. Mitoxantrone as initial induction treatment is at least as effective as daunorubicin when either drug is given in combination with cytarabine to patients with previously untreated ANLL. Complete response rates in randomised comparative trials were 53 to 67% after mitoxantrone with cytarabine and 37 to 70% after daunorubicin with cytarabine. In a major US study, significantly more patients achieved a complete response after 1 treatment cycle of mitoxantrone and cytarabine than after daunorubicin and cytarabine. Mitoxantrone has also been effective in inducing complete remissions in patients with relapsed or refractory ANLL, mainly in combination with other antineoplastic agents. Overall survival appears similar after treatment with regimens containing either mitoxantrone or daunorubicin in patients with ANLL, although there have been reports of trends towards increased survival rates with mitoxantrone. The incidence of cardiotoxicity appears low in patients with ANLL who have received mitoxantrone. Lower cardiotoxicity of mitoxantrone relative to daunorubicin has not been conclusively demonstrated in patients with ANLL, although trials in patients with breast cancer have shown mitoxantrone to cause fewer cardiac adverse effects than doxorubicin. This is of particular interest in the elderly, as this group of patients is especially susceptible to the effects of anthracycline-induced cardiac toxicity. Thus, mitoxantrone is a suitable first-line agent for the induction of remission in patients with ANLL, with clearly demonstrated efficacy in patients aged 60 years and over.

show abstract

Section: Cardiotoxicitymentioning

confidence: 99%

Mitoxantrone

Dunn¹,

Goa²

1996

Drugs & Aging

View full text Add to dashboard Cite

show abstract

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Thomas

Archimbaud

1997

Hematol Cell Ther

View full text Add to dashboard Cite

Mitoxantrone is an intravenous anthracenedione structurally related to the anthracycline antibiotics. This drug has been used for several years in the treatment of acute myelogenous leukemia (AML). Its use has been based on its pharmacological properties, its incomplete cross-resistance with other intercalating agents, and its better tolerance as predicted by preclinical studies. Various treatment schedules, using mitoxantrone alone and in combination with other antileukemic agents, have been used in clinical trials. Complete remission (CR) rates ranged from 14 to 44% in refractory AML and from 46 to 79% in relapsed patients. Although a superiority of mitoxantrone over anthracyclines has not been clearly demonstrated in newly diagnosed patients, mitoxantrone is now recognized as a useful drug in first line therapy. The tolerability profile of mitoxantrone indicates that it offers patients an acceptable quality of life compared with standard treatment regimens, and could be a good alternative to the anthracyclines. The development of new therapeutic concepts aiming at an optimization of its use is now in process and first results are promising.

show abstract

Mitoxantrone in the Treatment of Acute Leukemia

Cited by 2 publications

References 9 publications

Mitoxantrone

Mitoxantrone

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Contact Info

Product

Resources

About